All In Biotech

Drug Trial Radar · NCT02219711

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

193

Actual

Start

Aug 2014

Primary completion

Apr 27, 2022

Study completion Apr 27, 2022

Sponsor

Lead sponsor
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.

Conditions

  • Advanced Cancer

Interventions

  • MGCD516Drug

    MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Type of dose limiting adverse eventTime frame: Up to 3 weeks on treatment
  2. Area under the plasma concentration versus time curve (AUC) of MGCD516Time frame: Up to 72 hours
  3. Peak Plasma Concentration (Cmax) of MGCD516Time frame: Up to 72 hours

Locations

43 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • University of California, San Diego

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • Sarcoma Oncology Research Center

    Santa Monica, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Holy Cross Michael & Dianne Bienes Comprehensive Cancer Center

    Fort Lauderdale, Florida

  • Florida Cancer Affiliates

    Ocala, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Maryland Oncology Hematology,

    Rockville, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Washington University Center for Advanced Medicine

    St Louis, Missouri

  • CHI Health St Francis, Saint Francis Cancer Treatment Center

    Grand Island, Nebraska

  • Oncology Hematology West PC, Nebraska Cancer Specialists

    Omaha, Nebraska

  • University of New Mexico Cancer Research and Treatment Center

    Albuquerque, New Mexico

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Columbia University

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Oncology Hematology Care, Inc.

    Cincinnati, Ohio

  • Guthrie Clinical Research

    Sayre, Pennsylvania

  • St. Francis Cancer Center

    Greenville, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology-Austin Midtown

    Austin, Texas

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology-Tyler

    Tyler, Texas

  • The Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Oncology and Hematology Associates of Southwest Virginia, Inc., Blue Ridge Cancer Care

    Roanoke, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Northwest Cancer Specialists, P.C.

    Vancouver, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • National Cancer Center

    Goyang-si, South Korea

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.